AACR 2026

An abstract describing the study design for Isofol’s ongoing clinical phase Ib/II study with arfolitixorin has been accepted for presentation at the AACR in San Diego, US between April 17-22.

Information about the abstract

Title: ”Phase Ib/II study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC)”

Authors: Sebastian Stintzing, Arndt Stahler, Isabel Löwstedt, Marcus Thuresson, Roger Tell

Abstract number: CT218

Presentation: April 21 at 09:00 am – 12:00 pm

The abstract was published online on AACR’ s website and is also be available below: